SCHEMBL1127208

SCHEMBL1127208

COC(=O)C1CCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14146570 1.00
SCHEMBL11289082 0.88 SMN1; SMN2 (0.43)
SCHEMBL74560 0.86 TP53 (0.47)
SCHEMBL27737779 0.86 SMN1; SMN2 (0.46)
SCHEMBL4640326 0.83 CHRNB2 (0.38)
SCHEMBL4640319 0.83 CHRNB2 (0.38)
SCHEMBL4640325 0.83 CHRNB2 (0.38)
SCHEMBL12191578 0.81
SCHEMBL4641123 0.81 CHRNB2 (0.37)
SCHEMBL4640210 0.81 CHRNB2 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129094-A1 NEW QUINOLINE DERIVATIVES ELANCO ANIMAL HEALTH GMBH (DE) 2025-04-24 US claimed
EP-4399209-A1 NEW QUINOLINE DERIVATIVES Elanco Animal Health GmbH (DE) 2024-07-17 EP claimed
WO-2023036821-A1 NEW QUINOLINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-03-16 WO claimed
EP-4148052-A1 NEW QUINOLINE DERIVATIVES Bayer Animal Health GmbH (DE) 2023-03-15 EP claimed
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 EP disclosed
EP-4719603-A1 SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER Boehringer Ingelheim International GmbH (DE) 2026-04-08 EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 US disclosed
US-12551490-B2 Heterocyclic modulators of lipid synthesis SAGIMET BIOSCIENCES INC. (US) 2026-02-17 US disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 EP disclosed
EP-4646271-A1 SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES Mirati Therapeutics, Inc. (US) 2025-11-12 EP disclosed
EP-4633734-A1 COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING Wavebreak Therapeutics, LLC (US) 2025-10-22 EP disclosed
EP-4610260-A1 ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Shanghai Shenshi Wise Technology Co., Ltd. (CN) 2025-09-03 EP disclosed
EP-2124560-A1 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR Janssen Pharmaceutica, N.V. (BE) 2009-12-02 EP disclosed
WO-2009137391-A2 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-12 WO disclosed
WO-2009137391-A2 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-12 WO disclosed
WO-2009111279-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 WO disclosed
WO-2008100565-A1 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-21 WO disclosed
US-20080194577-A1 Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-14 US disclosed
US-6362346-B1 HEATING MIXTURE OF FUROIC ACID WITH ACID CATALYST E. I. DU PONT DE NEMOURS AND COMPANY 2002-03-26 US disclosed
US-6140545-A GAS PHASE HYDROGENATION OF CARBOXYLIC ACIDS OR ESTERS;HEATING, PRESSURIZATION BASF AKTIENGESELLSCHAFT (DE) 2000-10-31 US disclosed